v3.26.1
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Current assets:      
Cash and cash equivalents $ 8,482 $ 25,030  
Short-term investments 0 17,466  
Restricted cash 0 146  
Accounts receivable 1,253 1,482  
Inventories 0 10,655  
Other current assets 2,477 10,115  
Total current assets 12,212 64,894  
Property and equipment, net 73 1,294  
Operating lease assets 7,064 39,807  
Other assets 886 3,103  
Total assets 20,235 109,098  
Current liabilities:      
Accounts payable 127 4,367  
Accrued compensation 1,271 6,589  
Accrued research and development expenses 82 7,984  
Deferred revenue 716 95,092  
Liability related to the sale of future revenues - current portion 9,750 382  
Other current liabilities 2,976 20,160  
Total current liabilities 14,922 134,574  
Operating lease liabilities - long-term 9,347 29,914  
Liability related to the sale of future revenues - long-term 32,673 38,624  
Other long-term liabilities 1,795 3,269  
Total liabilities 58,737 206,381  
Commitments and contingencies (Note 9)  
Stockholders' equity (deficit):      
Common stock - $0.0001 par value, 500,000 shares authorized as of December 31, 2025 and 2024, respectively; 7,324 and 5,859 shares issued and outstanding as of December 31, 2025 and 2024, respectively 1 1  
Additional paid-in capital 1,983,361 1,957,261  
Accumulated other comprehensive income 1 8  
Accumulated deficit (2,021,865) (2,054,553)  
Total stockholders' equity (deficit) (38,502) (97,283) $ 99,231
Total liabilities and stockholders' equity (deficit) $ 20,235 $ 109,098  

Source

10-K
HTML PDF
XBRL
ZIP